Appendix B. Sources of Evidence

Appendix B. Sources of Evidence

1. The following documentation and opinion was made available to the Committee:

a. Assessment Report prepared by The School of Health and Related Research (ScHARR), University of Sheffield (A Review of the Clinical and Cost-Effectiveness of Gemcitabine for the Treatment of Pancreatic Cancer, December 2000)

b. Manufacturer/Sponsor submissions from:

  • Eli Lilly

c. Professional/Specialist Group submissions from:

  • Royal College of General Practitioners

  • Royal College of Physicians and the Royal College of Radiologists

d. Patient Group submissions from:

  • CancerBACUP

e. External expert and patient advocate submissions from:

  • Professor William Steward, Head, Department of Oncology, Leicester Royal Infirmary

  • Ms Judith Brodie, Head of Cancer Support Service, CancerBACUP